Every new e-cigarette or e-liquid product marketed in the US needs marketing authorisation from the FDA, usually through a Premarket Tobacco Product Application (PMTA). The applicant must show that marketing the product is “appropriate for the protection of public health”. This article explains what a PMTA contains and how the review works.
What does a PMTA contain?
Applicants must submit detailed scientific evidence and product information, mainly:
- Product composition and design: e-liquid ingredients, nicotine content, formulation, flavourings, product drawings, aerosolisation technology, battery parameters, etc.
- Harmful and potentially harmful constituents (HPHC) data: chemical analysis of the aerosol, for example formaldehyde, acetaldehyde, nitrosamines and heavy metals.
- Manufacturing and product consistency: evidence that mass-produced products remain consistent with the application, including manufacturing specifications, quality control parameters and release testing.
- User behaviour and public health impact: appeal to young people, effect on adult smokers switching or quitting, and data on how different user groups use the product.
- Toxicological assessment or human studies (where available): FDA does not necessarily require long-term clinical trials, but short-term use-behaviour studies or acute toxicity data strengthen an application.
Are clinical studies mandatory?
FDA’s PMTA guidance states that long-term clinical studies are generally not required. Published literature, in vitro toxicology, short-term inhalation studies and use-behaviour surveys, combined with third-party research data, can together form a complete scientific case.
This is good news for smaller companies: PMTA is about sound scientific support, not expensive studies. The key is a scientifically reasoned, rigorous and complete application.
How does the FDA review work?
- Pre-submission meeting (optional): request a meeting with FDA to discuss the application strategy and data types.
- Submission: the application is submitted electronically in the format specified by FDA (via the CTP Portal).
- Acceptance and filing review: FDA checks whether the application is complete enough to be accepted and filed; the applicant receives a submission tracking number.
- Substantive review: FDA evaluates the scientific data and may issue deficiency letters.
- Decision: if successful, FDA issues a Marketing Granted Order, which authorises the product to be marketed.
Note: a submission tracking number alone does not allow you to sell the product. It may only be marketed after FDA has issued a marketing granted order.
Recommendations for applicants
- Build the product file early: design records, ingredient lists, aerosol performance tests, battery safety data, etc.
- Ensure product consistency: samples must match future series production, with controlled quality, full batch traceability and production records.
- Work with qualified laboratories: carry out the necessary aerosol and toxicology testing so the data meet FDA expectations.
- Focus on youth-prevention measures: show that the product is not marketed to young people – labelling controls, age verification on websites, warning statements on packaging.
- Align with TPMP: base the manufacturing section of the PMTA on the proposed TPMP requirements to make it more credible.
How EVERBIZ can help
- PMTA strategy: from product planning to a tailored dossier structure.
- Data consolidation and writing: scientific summaries, risk assessments and other documents.
- Third-party testing: recommending qualified laboratories and helping interpret data.
- End-to-end submission and FDA communication: submission, deficiency responses and project tracking.
- TPMP: setting up a TPMP-ready quality system in parallel to stay compliant after authorisation.
We help you control costs, save time and improve your chances of authorisation. Contact us.
This article is for general information only and does not constitute legal advice.